Explaining the increase in coronary heart disease mortality in Syria between 1996 and 2006

被引:29
作者
Rastam, Samer [1 ,2 ]
Ali, Radwan A. L. [1 ]
Maziak, Wasim [1 ,3 ]
Mzayek, Fawaz [1 ,4 ]
Fouad, Fouad M. [1 ]
O'Flaherty, Martin [5 ]
Capewell, Simon [5 ]
机构
[1] Syrian Ctr Tobacco Studies, Aleppo, Syria
[2] Syrian Soc Against Canc Bldg, Syrian Ctr Tobacco Studies, St Aleppo, Shihan, Syria
[3] Florida Int Univ, Robert Stempel Coll Publ Hlth & Social Work, Miami, FL 33199 USA
[4] Univ Memphis, Sch Publ Hlth, Div Epidemiol & Biostat, Memphis, TN 38152 USA
[5] Univ Liverpool, Dept Publ Hlth & Policy, Liverpool L69 3BX, Merseyside, England
基金
英国医学研究理事会;
关键词
Coronary heart disease; Mortality; Modelling; ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; LATE REPERFUSION; ARTERY-DISEASE; STATIN THERAPY; METAANALYSIS; HEALTH; ASPIRIN; CLOPIDOGREL; FAILURE;
D O I
10.1186/1471-2458-12-754
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Despite advances made in treating coronary heart disease (CHD), mortality due to CHD in Syria has been increasing for the past two decades. This study aims to assess CHD mortality trends in Syria between 1996 and 2006 and to investigate the main factors associated with them. Methods: The IMPACT model was used to analyze CHD mortality trends in Syria based on numbers of CHD patients, utilization of specific treatments, trends in major cardiovascular risk factors in apparently healthy persons and CHD patients. Data sources for the IMPACT model included official statistics, published and unpublished surveys, data from neighboring countries, expert opinions, and randomized trials and meta-analyses. Results: Between 1996 and 2006, CHD mortality rate in Syria increased by 64%, which translates into 6370 excess CHD deaths in 2006 as compared to the number expected had the 1996 baseline rate held constant. Using the IMPACT model, it was estimated that increases in cardiovascular risk factors could explain approximately 5140 (81%) of the CHD deaths, while some 2145 deaths were prevented or postponed by medical and surgical treatments for CHD. Conclusion: Most of the recent increase in CHD mortality in Syria is attributable to increases in major cardiovascular risk factors. Treatments for CHD were able to prevent about a quarter of excess CHD deaths, despite suboptimal implementation. These findings stress the importance of population-based primary prevention strategies targeting major risk factors for CHD, as well as policies aimed at improving access and adherence to modern treatments of CHD.
引用
收藏
页数:9
相关论文
共 62 条
  • [41] Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials
    Pignone, M
    Phillips, C
    Mulrow, C
    [J]. BRITISH MEDICAL JOURNAL, 2000, 321 (7267) : 983 - 986
  • [42] The effect of spironolactone on morbidity and mortality in patients with severe heart failure
    Pitt, B
    Zannad, F
    Remme, WJ
    Cody, R
    Castaigne, A
    Perez, A
    Palensky, J
    Wittes, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (10) : 709 - 717
  • [43] Reddy KS, 1998, CIRCULATION, V97, P596
  • [44] Cardiovascular diseases in the developing countries: dimensions, determinants, dynamics and directions for public health action
    Reddy, KS
    [J]. PUBLIC HEALTH NUTRITION, 2002, 5 (1A) : 231 - 237
  • [45] Roohafza H, 2009, ARYA ATHEROSCLER, V5, P109
  • [46] Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
    Sabatine, MS
    Cannon, CP
    Gibson, CM
    Lopez-Sendon, JL
    Montalescot, G
    Theroux, P
    Claeys, MJ
    Cools, F
    Hill, KA
    Skene, AM
    McCabe, CH
    Braunwald, E
    Braunwald, E
    Cannon, C
    Sabatine, M
    McCabe, C
    McCagg, A
    Job, B
    Gaudin, C
    Thizon-de Gaulle, I
    Blumenthal, M
    Saini, R
    Delaet, I
    Townes, L
    Anhalt, D
    van Holder, K
    Skene, A
    Hill, K
    Braunwald, E
    Cannon, C
    Sabatine, M
    McCabe, C
    Job, B
    Gaudin, C
    Thizon-de Gaulle, I
    Blumenthal, M
    Saini, R
    Delaet, I
    Townes, L
    Skene, A
    Ardissino, D
    Aylward, P
    Bertrand, M
    Bode, C
    Budaj, A
    Claeys, M
    Dellborg, M
    Ferreira, R
    Gershlick, A
    Huber, K
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (12) : 1179 - 1189
  • [47] SCHOEN R, 1970, DEMOGRAPHY, V7, P317, DOI 10.2307/2060150
  • [48] Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure
    Shibata, MC
    Flather, MD
    Wang, DL
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2001, 3 (03) : 351 - 357
  • [49] State Planning commission of Syrian Arab Republic, 2006, 10 5 YEARS PLANN 200
  • [50] Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
    Tavazzi, Luigi
    Maggioni, Aldo P.
    Marchioli, Roberto
    Barlera, Simona
    Franzosi, Maria Grazia
    Latini, Roberto
    Lucci, Donata
    Nicolosi, Gian Luigi
    Porcu, Maurizio
    Tognoni, Gianni
    [J]. LANCET, 2008, 372 (9645) : 1231 - 1239